Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Trial Profile

A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs GDC-9545 (Primary) ; Gonadotropin releasing hormone; Palbociclib
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 16 Nov 2018 Planned number of patients changed from 130 to 150.
    • 31 Aug 2018 Biomarkers information updated
    • 11 May 2018 Planned End Date changed from 28 Nov 2020 to 31 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top